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TIIVISTELMÄ
Samanaikainen alkoholiriippuvuus ja vakava masennustila on haasteellista sekä
lääketieteelliselle hoidolle että tutkimukselle. Tämä oireyhtymä on yksi yleisimmistä
psykiatrisista häiriöistä niin Yhdysvalloissa kuin Suomessakin. Potilaiden ja heidän
omaistensa inhimillisen kärsimyksen lisäksi myös kokonaistaloudelliset tervey-
denhoidolliset kustannukset ovat suuret tämän oireyhtymän hoidossa: niiden arvioi-
daan olevan yli neljäkymmentä prosenttia korkeammat kuin pelkän depression kohdalla.
Tässä tutkimuksessa pyrittiin löytämään uusia hoidollisia vaihtoehtoja
alkoholiriippuvuudesta ja vakavasta masennuksesta yhtäaikaisesti kärsivien potilaiden
hoidossa. Tutkimukseen osallistui 80 potilasta Helsingin kaupungin kolmelta A-klinikalta.
Kyseessä oli kaksoissokko, randomisoitu, kahden eri tavalla vaikuttavan lääkkeen,
essitalopraamin (selektiivinen serotoniinin takaisinoton estäjä) ja memantiinin
(glutamaatin NMDA reseptorin ei-kilpaileva estäjä) vertaileva tutkimus. Potilaiden
oireiden kulkua seurattiin 26 viikkoa depressioon, ahdistuneisuuteen, kognitioihin,
elämänlaatuun ja alkoholin käyttöön liittyvillä mittareilla. Tämän jälkeen tarkasteltiin
hoitovastetta alkutilanne- ja taustamuuttujien valossa. Pyrkimyksenä oli löytää joitakin
ennustekijöitä, joiden pohjalta kliinikko voisi tehdä hoitoratkaisunsa näiden potilaiden
hoidossa.
Molemmat lääkkeet vähensivät merkittävästi sekä masennusta että ahdistuneisuutta, eikä
essitalopraami- ja memantiiniryhmien välillä ollut tilastollisesti merkitsevää eroa.
Kognitiiviset toiminnot olivat lähtövaiheessa normatiivisella tasolla. Elämän laatu parani
molemmissa hoitoryhmissä. Alkoholimittareilla AUDIT (alkoholihäiriöiden tunnistusmittari)
ja OCDS (pakkomielteisen ja pakkotoimintoisen alkoholinkäytön mittari) paranivat
molemmissa hoitoryhmissä.
8Varhainen ensimmäisen vakavan masennuksen episodin alku näytti ennakoivan huonoa
vastetta essitalopraamille, mutta ei memantiinille, mitattuna Montgomery-Åsberg depression
rating scale -asteikolla. Toisaalta myöhäinen ensimmäisen masennuksen episodi näytti
ennakoivan hyvää hoitovastetta essitalopraamille. Niinpä ensimmäisen masennuksen
alkamisikä saattaisi olla käyttökelpoinen ennustekijä näille lääkkeille.
AUDIT-mittarilla mitattuna varhainen ensimmäisen masennuksen alkamisikä ennusti huonoa
hoitovastetta essitalopraamille samoin kuin humalahakuisen juomisen alkamisikä. Aktiivinen
alkoholinkäyttö tutkimuksen alkaessa ennakoi tutkimuksen keskeyttämistä.
HTTLPR-geenin L-alleeli näytti ennustavan parempaa hoitovastetta essitalopraamille kuin
S-alleeli.
Avansanat: Alkoholismi; Sitalopraami; Glutamiinihappo; Vakava masennus; Serotoniinin
takaisinoton estäjät; Serotoniinitransportterin geenivaihtelu; Ennustetekijät
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ABSTRACT
The treatment of comorbid alcohol dependence and major depression is a challenge to
medical research and practice. This comorbidity is one of the most common psychiatric
disorders in the United States and also in Finland. Besides the human suffering of both
patients and their relatives, the economical costs of total medical care of this
comorbidity are over forty percent higher than those of depression alone.
The aim of this research was to find out some new treatment options for these patients.
There were 80 patients recruited from municipal alcohol-clinics in Helsinki, who were
subjected to a double-blind, randomized trial with two differently acting medicines,
escitalopram (selective serotonin transporter inhibitor) and memantine (glutamate
N-methyl-D-aspartate receptor partial antagonist). The patients were followed 26 weeks for
depression, anxiety, cognition, quality of life and drinking measures. After that phase,
the treatment response was looked for from the baseline data to ascertain if there were
any predictive signs which would be beneficial for clinicians when planning the treatment
for these patients.
Both treatments reduced the baseline level of depression and anxiety and there was no
significant difference between the memantine and the escitalopram groups. Assessed
cognitive functioning scored primarily within the normative ranges. Quality of life
improved in both treatment groups. Alcohol measures Alcohol Use Disorders Identification
Test (AUDIT) and Obsessive Compulsive Drinking Scale (OCDS) improved in both treatment
groups.
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The early onset of the first major depressive episode seemed to predict poor response to
escitalopram, but not to memantine, when measured with the Montgomery-Åsberg Depression
Rating Scale. Vice versa, the late onset of the first depressive episode seemed to predict
good response to escitalopram. So the age at the first depressive episode might be a
relevant predictor to these treatments.
When measured drinking by AUDIT, the early onset of the first depressive episode and the
early onset of intoxicative drinking seemed to predict poor response to escitalopram. The
active drinking at the time of the beginning of the study, predicted early termination of
the treatment with both medicines.
The long variant allele of the 5-hydroxy tryptamine transporter linked polymorphic region
(5-HTTLPR) gene predicts better treatment response to escitalopram compared to the short
variant allele.
Keywords: Alcoholism; Escitalopram; Memantine; Major Depressive Disorder; 5-HTTLPR ;
Predictors
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1   INTRODUCTION
Alcohol dependence and alcohol abuse are significant public health problems in Finland
(Pirkola et al. 2005) and all over the world (Kessler et al. 2005; Kessler et al. 1997).
The 12-month prevalence of alcohol dependence was 3.9% in Finnish Health 2000 survey in
the population over the age of 30 years (Pirkola et al. 2005). The lifetime prevalence of
alcohol dependence was 5.4% in the USA over the age of 18 years in the National
Comorbidity Survey Replication (NCS-R) (Kessler et al. 2005). The lifetime prevalence of
alcohol abuse was 14.1 % (men 20.1%; women 8.2%) in the National Comorbidity Survey
(NCS) (Kessler et al. 1997); and 13.7% in men and 4.1% in women in the Cross-National
Comparison (CNC) in the Seven Surveys (Kessler et al. 2003).
In the Finnish Health 2000 survey, the 12-month prevalence of Major Depressive Disorder
(MDD) was in Finland 4.9%, and the prevalence of comorbidity with alcohol dependence in
Finland in year 2000 was 0.4% (Pirkola et al. 2005). The lifetime prevalence of major
depression was 16.6 % and co-occurrence of alcohol dependence with depressive disorders
was common: 24.3% in men and 48.5% in women according to the NCS (Kessler et al. 1997)
and 18.1% in men and 41.2% in women according to the CNC (Kessler et al. 2003). In research
of major depressive outpatients, 11.9% had comorbid alcohol abuse/dependence (Rush et al.
2005). Both alcohol dependence and major depression pose a significant risk for the
development of the other disorder at 1 year after onset (Gilman and Abraham 2001).
Concurrent depression and alcoholism lead to greater disability than alcoholism alone
(Oslin et al. 1999; Thase et al. 2001). The lifetime suicide rate in alcoholism is
estimated to range from 2% to 18% (Pirkola et al. 2004; Sher et al. 2005) and in
depression from 2% to 15% (Sher et al. 2005). Comorbidity increased the risk of suicide
among depressive patients 2.1 times (Sher et al. 2005). Major depression occurring before
substance dependence predicted severity of suicidal intent, and major depression occurring
during abstinence predicted number of suicidal attempts (Aharonovich et al. 2002). Besides
human suffering, this comorbidity leads to higher total medical care expenditures, which
are 44% higher than those for patients with depression alone (Mark 2003).
The medical treatment of MDD comorbid with alcohol dependence is difficult and
controversial. Antidepressant medication exerts a modest beneficial effect for these
patients and more research is warranted both to diagnostic field and treatment of this
comorbidity (Nunes and Levin 2004). Sobriety has marked and early, globally averaged and
regionally specific morphological, metabolic as well as functional benefits for
convalescent alcoholics (Bartsch et al. 2007), and should be encouraged before treatment
of depression (Nunes and Levin 2006). However, for many patiens the requirement of
sobriety is too demanding (Baekeland and Lundwall 1975). The aim of this research was to
find out some new treatment alternatives in the treatment of comorbid alcohol dependence
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and major depression. In addition to this, another aim was to find out some predictive
signs for clinicians when making decisions of medical treatment for this comorbidity. The
exclusion of the division of patients to "primary depressive" or "secondary depressive"
groups was made because the assumption was that it was unknown whether the depression was
primary or secondary, even when it appeared after long-lasting alcohol dependence. The
study was based on double-blind, randomized comparison of two differently acting
compounds, memantine, a non-competitive antagonist of glutamate NMDA receptor, and
escitalopram, a selective serotonin reuptake inhibitor. Memantine was choosen because its
neuroprotective properties and similarity with acamprosate, a compound the US Food and
Drug Administration (FDA) approved for the treatment of alcohol dependence.
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2   REVIEW OF THE LITERATURE
2.1 Neurobiology of ethanol
Several neurotransmitter systems in different brain areas contribute to the
neurobiological basis of alcoholism. Involvement of neurotransmitters and neuropeptides,
as well as ligand-gated ion channels have not been fully examined and understood but they
are under intensive research. Neuropharmacologic studies in animal models have provided
evidence for specific neurochemical mechanisms in specific brain reward and stress
circuits that become dysregulated during development of alcohol dependence (Koob 2003).
Several neurotransmitters are involved in the different components of alcohol dependence.
Glutamate and γ-aminobutyric acid (GABA) are considered to be the primary transmitters
mediating alcohol effects (Zigmond et al. 1999).
Glutamate receptors regulate neuronal differentiation, synaptic plasticity and memory
(McDonald and Johnston 1990). These receptors are linked to ligand-gated ion channels that
are activated by the neurotransmitter glutamate and are critically involved in many forms
of synaptic plasticity including those associated with learning and memory (Woodward et
al. 2006). The capacity to block N-methyl-D-aspartate (NMDA) glutamate receptors may be
one of the most important influences of alcohol in the brain (Krystal et al. 2003).
Alcohol affects glutamatergic transmission in three ways: by interfering with fast
excitatory neurotransmission, by promoting excitotoxity, and by impairing neurodevelopment
(Tsai et al. 1995). Acutely, ethanol reduces excitatory glutamatergic synaptic
neurotransmission (Lovinger et al. 1989). Chronic ethanol administration upregulates NMDA
receptor function and contributes to ethanol tolerance (Krystal et al. 2003).
Glutamatergic transmission belongs to mechanisms playing important roles in the process
underlying the development and maintenance of addiction (Tzschentke and Schmidt 2003).
Upregulation of NMDA receptors could contribute to development of alcohol deprivation
effect (Sinclair and Senter 1967) that is expressed as increased craving for alcohol after
an abstinence period (Sinclair 1980). Ethanol induced acute attenuation of NMDA receptor
neurotransmission after chronic upregulation of NMDA receptors is supposed to be
responsible for "black-out" related to alcohol intoxication (Tsai and Coyle 1998), which
is assumed to arise from impaired long-term potentiation, a cellular analogue to recent
memory (Kauer et al. 1988).
While glutamatergic neurotransmission is excitatory and mediates signals via Calcium,
Natrium and Magnesium -ions, GABAergic neurotransmission is inhibitory and mediates
signals via Cloride-ions (Zigmond et al. 1999). At concentrations that are present during
acute intoxication, alcohol stimulates GABA receptor mediated chloride flux in rat
cerebral cortex (Suzdak et al. 1986). GABA contributes to motor-impairing (Hellevuo et al.
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1989), sedative and anxiolytic-like effects of ethanol (Liljequist and Engel 1984) and
aggressive behavior caused by cortical disinhibition (Begleiter and Porjesz 1999; Miczek
et al. 1997). After chronic use, the adaptative changes in this neurotransmitter system
are thought to underlie partly the development of alcohol dependence (Grobin et al. 1998).
One hypothesis is that GABAergic interaction with the brain stress neurotransmitter
corticotrophin-releasing factor may be an important component for the transition from
social drinking to addiction (Koob 2004).
In acute use, ethanol increases the level of serotonin in nucleus accumbens (Yoshimoto et
al. 1992). Alcoholics that use large quantities of alcohol show evidence of differences in
brain serotonin levels compared with non-alcoholics (Lovinger 1997). Type 2 alcoholism
(Cloninger et al. 1981; Cloninger et al. 1988), e.g. early onset of alcohol abuse and
antisocial, impulsive and violent behavior, has been found to be associated with low
cerebrospinal fluid serotonin metabolite 5-hydroxy indole acetic acid (5-HIAA)
concentration (Virkkunen and Linnoila 1993) and with low activity serotonin transporter
promoter genotype (Hallikainen et al. 1999). The activation of serotonin receptors also
modifies the activity of the neurotransmitter dopamine, which, like serotonin, modulates
neuronal activity (Lovinger 1997).
Alcohol intake increases the level of dopamine in nucleus accumbens (Weiss et al. 1993).
The activation of dopaminergic system produces euphoria (Wise and Bozarth 1985). Alcohol
increases firing of dopamine neurons in the ventral tegmental area by activating GABAA
receptors or by inhibiting NMDA receptors (Cami and Farre 2003). The ability of alcohol to
produce reinforcing qualities on emotional contents and motivational status has been
linked to alcohol’s addiction potential (Chastain 2006). The present receptor data from
animal and especially human studies are emphasizing the importance of Dopamine 2 receptors
in alcohol dependence (Tupala and Tiihonen 2004).
Also other transmitter systems are emerging as mediators of alcohol reward. Acute ethanol
exposure leads to an increase in extracellular adenosine, activating nucleus accumbens,
which is supposed to play a significant role in reinforcement and reward, and mediation of
voluntary alcohol consumption (Mailliard and Diamond 2004). Neuropeptide Y and the
endogenous opioid peptide system have been hypothesized to be involved in reinforcing
effects of alcohol (Reid and Hunter 1984). Norepinephrine has a significant role in
modulating ethanol-related behaviors and psychological responses (Weinshenker et al.
2000). The activation of cannabinoid CB 1 receptor promotes alcohol reward (Basavarajappa
and Hungund 2002) and cannabinoid CB 1 receptor antagonist is supposed to suppress various
alcohol-related behaviors (Colombo et al. 2007). Active alcohol intake in chronic
alcoholism may increase spontaneous production of interleukines and other cytokines (Laso
et al. 2007), which may, interfering with serotonergic systems, cause depressive illness
(Dunn et al. 2005).
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2.2 Neurobiological connection between alcohol dependence,
depression and cognition
Hippocampus is proposed to be an important site of alcohol influence in the brain in the
development of alcohol dependence. Hippocampal dysfunction and neurodegeneration are
common results from the neurotoxic effects of alcohol. Events related to hippocampal
neurogenesis such as learning, memory, and mood are dysregulated in chronic alcoholism
(Nixon 2006). Considering the importance of hippocampus in major depression (Mervaala et
al. 2000) and cognition (Parsons 1994), chronic alcohol exposure reduces hippocampal
neurogenesis and dendritic growth in newborn neurons (He et al. 2005). There is evidence
that adult hippocampal neurogenesis may be regulated by NMDA receptors present in
precursor cells (Nacher et al. 2007).
Alcoholism is associated with a range of memory and executive deficits leading to mild
generalized dysfunction of the brain which results in a variable pattern of impairment in
perceptual-motor skills, visual-spatial functions, learning, memory, and abstraction and
problem solving (Parsons and Nixon 1993). As much as 10% of dementias are supposed to be
alcohol related (Oslin and Cary 2003). Neurodegeneration is at present thought to be a
consenquence of a failure in normal regeneration in brain regions that contain
neurogenesis, such as the hippocampus. Some drugs interacting with glutamate receptors
have shown to be neuroprotective, such as metabotrophic glutamate receptor antagonist
acamprosate (De Witte et al. 2005) and the ionotropic glutamate receptor antagonist
memantine (Parsons et al. 1999). Ethanol regulates proliferation of glia and a lower
number of glia was found in the cortex in depression (Rajkowska and Miguel-Hidalgo 2007).
Depression as such is associated with memory and executive deficits (Veiel 1997), which
are presumed to be related to reduced cerebral activation in medial and dorsolateral
prefrontal cortex and correlate to severity of depression (Buchsbaum et al. 1997). Major
depression is associated with a selective loss of hippocampal volume that persists long
after the depression has resolved (Sapolsky 2000b). Serotonin has been shown to produce
long-lasting facilitation of synaptic transmission in the amygdala, and to have a possible
synaptic role in long-term memory for learned fear. This long-term effect of serotonin may
be very important for the long-term storage of amygdala-based emotional behavior (Huang
and Kandel 2007). Recently it was suggested that the intensity of past depression
contributes to the impairment of memory due to toxic link between the burden of depression
and cognition (Gorwood et al. 2008). The antidepressant treatment reverses the decreases
in neurogenesis following chronic alcohol drinking (Malberg et al. 2000). The failure in
normal neuroregeneration provides a new aspect for understanding psychiatric diseases
related to chronic alcoholism (Nixon 2006). In a Finnish study, the volume of the left
hippocampus was significantly smaller in the group of severe depressive patients compaired
with the controls (Mervaala et al. 2000), which is associated with hypersecretion of
glucocorticoids (Sapolsky 2000a) and imbalance in the activity of
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hypothalamus-pituitary-adrenal (HPA) axis (McEwen 2005). In a study of cognition in
remitted major depression patients, the deficits in executive functions in MDD worsened
during chronic course of depression (Paelecke-Habermann et al. 2005). Chronic alcohol use
leads to reduced brain levels of β-endorphin, which contribute to negative emotional
states (Herz 1997) related to depression (Heinz et al. 2001). It is supposed that
depression could contribute to the pattern of cognitive impairment in alcoholism (Penick
et al. 1994). This hypothesis was investigated by evaluating depression and cognitive
functioning of alcoholics, and the results suggested that the deficits were not generally
exacerbated by comorbid depressive symptoms (Uekermann et al. 2003).The brain
glutamatergic system, with its NMDA receptors, is suggested to be involved in toxic
neuronal loss due to an increased glutamatergic neurotransmission during repeated alcohol
withdrawal (Tsai et al. 1995).
Some NMDA-antagonists ameliorate cognitive deficits in adult rats withdrawn from chronic
ingestion of alcohol (Lukoyanov and Paula-Barbosa 2001). In addition, the Selective
Serotonin Reuptake Inhibitors (SSRI) were shown to be neuroprotective in a preclinical
study, as long-term (2-4 weeks) administration resulted in upregulation of neurogenesis
(Li et al. 2003). In a preliminary study, it was shown that one year treatment with SSRI
led to significant increase in hippocampal volume and increase in memory functioning in
posttraumatic stress disorder (Bremner 2006). Antidepressant therapy following stroke
fostered long-term improvement of executive function (Narushima et al. 2007).
Figure 1. Serotonergic pathways and Distribution of Glutamate receptors.
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2.3 Alcohol Dependence
2.3.1 Definition of alcohol dependence
The development of alcohol dependence requires both the use of alcohol and the
vulnerability to dependence. Alcohol dependence is described in the Diagnostical and
Statistical Manual of Mental Disorders, Text Revision (DSM-IV TR)(American Psychiatric
Association 2000), as a subtype of Substance Dependence, as a cluster of cognitive,
behavioral, and physiological symptoms indicating that the individual continues use of
alcohol despite significant alcohol-related problems (criteria in table 1).
Table 1. DSM-IV TR criteria for Alcohol Dependence. 
A maladaptative pattern of alcohol use, leading to clinically significant impairment or
distress, as manifested by three (or more) of the following, occurring at any time in the
same 12-month period:
(1) tolerance, as defined by either of the following:
    (a) a need for markedly increased amounts of the alcohol to achieve intoxication or
          desired effect
    (b) markedly diminished effect with continued use of the same amount of the alcohol
(2) withdrawal, as manifested by either of the following:
    (a) the characteristic withdrawal syndrome for the alcohol
    (b) alcohol is taken to relieve or avoid withdrawal symptoms
(3) alcohol is often taken in larger amounts or over a longer period than was intended
(4) there is persistent desire or unsuccessful efforts to cut down or control alcohol use
(5) a great deal of time is spent in activities necessary to obtain the alcohol (e.g.,
    driving long distances), use alcohol or recover from its effects
(6) important social, occupational, or recreational activities are given up or reduced
    because of alcohol use
(7) the alcohol use is continued despite knowledge of having a persistent or recurrent
    physical or psychological problem that is likely to have been caused or exacerbated
    by the substance (e.g. continued drinking despite that an ulcer was made worse by
    alcohol consumption)
Diagnosis of substance dependence, to the appropriate extent, according Diagnostic and
Statistical Manual of Mental disorders, Fourth Edition (DSM-IV), Text Revision (American
Psychiatric Association, 2000)
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2.3.2 Glutamate and alcohol dependence
Glutamate is the major excitatory amino acid in the central nervous system. It and related
amino acids are thought to be utilized by 40 percent of synapses (Coyle and Puttfarcken
1993). Repeated bouts of high alcohol consumption induce an imbalance between inhibitory
and excitatory neurotransmission within nucleus accumbens that may drive excessive
drinking behavior (Szumlinski et al. 2007). Long term alcohol use increases the number of
glutamate NMDA receptors (Nagy 2004), alters the function of NMDA receptors (Petrakis et
al. 2004), and leads to ethanol tolerance (Nagy 2004). The glutamate antagonist treatment
reduces ethanol-seeking and relapse behavior in rats (Backstrom et al. 2004). Animal
studies have shown that memantine, an uncompetitive NMDA receptor antagonist, decreases
alcohol drinking (Bachteler and Spanagel 2005; Holter et al. 1996). Memantine also reduced
alcohol drinking in rats when the access to alcohol was limited to a short period daily
(Piasecki et al. 1998), and in mice when alcohol drinking had been increased by
schedule-induced polydipsia (Escher et al. 2006). Memantine has been shown to block
ethanol-induced upregulation of NMDA receptors (Maler et al. 2005).
Similar effects on alcohol drinking in humans have been found with other NMDA receptor
blockers (Bachteler et al. 2005; Holter et al. 2000; Vengeliene et al. 2005) including
acamprosate (Bouza et al. 2004; Heyser et al. 1998; Spanagel et al. 1996). Acamprosate is
a weak NMDA modulator, which acts on metabotrophic glutamate receptors. It is already in
use for treating alcohol dependence (Kranzler and Van Kirk 2001). Although the results of
the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence
(COMBINE study) (Anton et al. 2006), found no superiority of acamprosate compared with
placebo, it was found to significantly reduce relapse rates in alcohol dependence in
several placebo-controlled double-blind trials (Soyka and Roesner 2006). In patients
motivated to achieve abstinence, acamprosate seems to be an effective treatment (Pettinati
and Rabinowitz 2006). Similar effects in alcohol dependent patients have been reported
with oxcarbazepine, which reduces glutamatergic transmission at corticostriatal synapses
(Croissant et al. 2006), and topiramate, that may partly act as an antagonist at some
glutamate receptors (Johnson et al. 2007).
In a study examining the effects of memantine on alcohol use in humans, memantine
suppressed the craving for alcohol in moderate drinkers, when they were deprived, but not
later when they were drinking (Bisaga and Evans 2004). In a study reporting effects of
memantine on cue-induced alcohol craving in recovering alcohol-dependent patients after
detoxification, memantine did not stimulate alcohol craving before exposure to an alcohol
cue, and it attenuated cue-induced craving for alcohol in a dose-related fashion
(Krupitsky et al. 2007).
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2.3.3 Serotonin and alcohol dependence
Serotonin plays a role in regulation of mood, appetite, arousal, sleep, pain and many
other behaviors (Roth 1994). In animal studies, it was found that the levels of serotonin
and its metabolites were lower in cerebrospinal fluid of alcohol preferring rats than in
non-preferring rats (McBride et al. 1995) and alcohol preferring monkeys (Heinz et al.
2001). Alcohol preferring rats also had a lower number of serotonin neurons than the
non-preferring rats (Zhou et al. 1994). Various animal studies have shown that voluntary
alcohol drinking by rats was reduced by compounds that increase serotonergic actions (Amit
et al. 1984; McBride et al. 1992; Naranjo et al. 1986), including zimilidine, viqualine
and fluoxetine.
Preliminary clinical work supported the efficacy of zimilidine, one of the first SSRIs, in
human alcoholics (Naranjo and Bremner 1992). A similar but safer compound, citalopram, was
found to be effective in treating human alcohol dependence (Naranjo et al. 1986). In
alcoholism without depression, SSRIs have shown positive results in reducing drinking,
especially when the drinking has not initially been severe (Balldin et al. 1994;
Hautzinger et al. 2005; Naranjo and Knoke 2001a; Pettinati et al. 2001; Tiihonen et al.
1996).
2.4 Major depressive disorder
2.4.1 Definition of major depressive disorder
Major depressive disorder (MDD) is described in the Diagnostical and Statistical Manual of
Mental Disorders, Text Revision (DSM-IV TR)(American Psychiatric Association 2000) and
characterized by one or more Major Depressive Episodes (MDE) (criteria in table 2).
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Table 2. DSM-IV TR Criteria for Major Depressive Episode. 
A. Five (or more of the following symptoms have been present during the same 2-week period
and represent a change from previous functioning; at least one of the symptoms is either
(1) depressed mood or (2) loss of interest or pleasure:
     (1) depressed mood most of the day, nearly every day, as indicated by either subjective
         report (e.g., feels sad or empty) or observation made by others (e.g., appears tearful)
     (2) markedly diminished interest or pleasure in all, or almost all, activities most of the
         day, nearly every day (as indicated by either subjective account or observation made by
         others)
     (3) significant weight loss when not dieting or weight gain (e.g., a change of more than
         5% of body weight in a month), or decrease or increase in appetite nearly every day
     (4) insomnia or hypersomnia nearly every day
     (5) psychomotor agitation or retardation nearly every day (observable by others, not
         merely subjective feelings of restlessness or being slowed down)
     (6) fatigue or loss of energy nearly every day
     (7) feelings of worthlessness or excessive or inappropriate guilt (which may be
         delusional) nearly every day (not merely self reproach or guilt about being sick)
     (8) diminished ablity to think or concentrate, or indecisiveness, nearly every day (either
         by subjective account or as observed by others)
     (9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation
         without specific plan, or a suicide attempt or a specific plan for committing suicide
B. The symptoms do not meet criteria for a Mixed Episode.
C. The symptoms cause clinically significant distress or impairment in social,
occupational, or other important areas of functioning.
D. The symptoms are not due to the direct physiological effects of a substance (e.g., drug
of abuse, a medication) or a general medical condition (e.g., hypothyroidism).
E. The symptoms are not better accounted for by Bereavement, i.e.., after loss of a loved
one, the symptoms persist for longer than 2 months or are characterized by marked
functional impairment, morbid preoccupation with worthlessness, suicidal ideation,
psychotic symptoms, or psychomotor retardation.
Diagnosis of bipolar disorder, to the appropriate extent, according Diagnostic and
Statistical Manual of Mental disorders, Fourth Edition (DSM-IV), Text Revision (American
Psychiatric Association, 2000)
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2.4.2 Glutamate and major depression.
Glutamate NMDA receptors have been implicated in crucial physiological processes, such as
synaptogenesis, learning and memory (Heresco-Levy and Javitt 1998). In addition to
participation in synaptic transmission and neuronal plasticity, NMDA receptors also play a
crucial role in the regulation of neuronal development and connectivity (Cline and
Constantine-Paton 1990). Both competitive and non-competitive antagonists of NMDA
receptors reduced the behavioral deficit in an animal model of depression comparable to
imipramine (Papp and Moryl 1994). In a recent animal study, the compound ceftriaxone, a
beta-lactam antibiotic that stimulates uptake of glutamate, demonstrated
antidepressant-like effects in several mouse models (Mineur et al. 2007). In animal
studies, memantine produced antidepressive-like activity (Ljungberg 1986; Moryl et al.
1993).
There is increasing evidence from neuroimaging studies that severe mood disorders are
associated with impairments of structural plasticity and cellular resilience (Manji et al.
2003) and that NMDA-receptors have a significant role in mood disorders (Sanacora et al.
2003) by dysregulation of neurotransmission via NMDA receptors (Pittenger et al. 2007).
These aspects are proposed to represent new ways to both understanding depressive
symptomatology and developing more effective antidepressants (Paul and Skolnick 2003).
A recent study revealed elevated glutamate levels in the occipital cortex in
medication-free subjects with major depressive disorder compared with healthy controls
(Sanacora et al. 2004). In human suicide victims, selective alterations in the glutamate
recognition site and its coupling to the co-transmitter glycine site were demonstrated
(Nowak et al. 1995). In a study of refractory affective disorder, cerebrospinal fluid
glutamate was reduced significantly in patients compared to controls (Frye et al. 2007)
Some NMDA modulators, such as D-cycloserine and amantadine, have shown to possess
antidepressant effect when used in the treatment of tuberculosis and Parkinson’s disease
(Kugaya and Sanacora 2005). A glutamate antagonist topiramate, a medication for seizure
disorders, has been shown to be effective in the reduction of depressive symptoms and
anger in depressive women (Nickel et al. 2005). Lamotrigine, a compound that is used to
treat bipolar depression, decreases glutamate transmission (Hurley 2002; McElroy et al.
2004). It was shown that intravenous injection of the NMDA antagonist, ketamine, is
effective for patients with treatment-resistant MDD (Krystal et al. 1998; Zarate et al.
2006a). The NMDA modulator riluzole was found to be effective in a preliminary study in
treatment-resistant depression (Zarate et al. 2004) and in residual depressive symptoms
with antidepressant treatment (Sanacora et al. 2006). A novel finding is that patients
with major depressive disorder had reduced glutamate levels in both prefrontal region of
interest (Hasler et al. 2007) and a link between an increase in glutamatergic metabolites
in prefrontal brain areas and rapid antidepressive manipulations (Murck et al. 2008).
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2.4.3 Serotonin and major depression
The diminished availability of serotonin is one of the crucial factors in depression
(Meltzer 1989). Over thirty years ago, it was supposed that the concentration of serotonin
in the cerebrospinal fluid correlates with the severity of depression in those patients,
whose serotonin turnover is disturbed (Asberg et al. 1976). In a recent neuroimaging
study, patients with MDD had significant lower serotonin transporter binding potential in
the midbrain region than controls (Joensuu et al. 2007). The altered serotonin activity is
one premise for the use of selective serotonin reuptake inhibitors (SSRIs) in the
treatment of depressive disorders (Owens and Nemeroff 1994). SSRIs were developed for
inhibition of the neuronal uptake pump for serotonin. The therapeutic mechanism of action
of SSRIs involves alteration in the serotonin system. There are several studies and
meta-analyses of SSRIs in the treatment of depressive disorders. The first SSRI approved
as antidepressant was zimelidine. It was withdrawn from the market due to the report of
Guillain-Barre syndrome in a few patients. Over a relatively short period occurred the
development of five other SSRIs, namely fluoxetine, fluvoxamine, sertraline, paroxetine
and citalopram (Vaswani et al. 2003). The more efficient compound escitalopram, the
S-enantiomer of citalopram, is now widely used for the treatment of depression (Thase
2006). The treatment of major depression with SSRIs is widely accepted and recommended in
Finnish recommendation for treatment of depression (Isometsä et al. 2005).
Even when there is a risk of increased suicide attempts in depressive patients treated
with SSRIs (Jick et al. 2004), the mortality rate among these patients has shown to
decrease (Tiihonen et al. 2006).
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Figure 2. Treatment Studies of Alcohol- Related Disorders and Comorbid Depressive Disorder. 
      Outcomes of Treatments for Individuals with Alcohol-Related Disorder and Comorbid Depressive Disorder 
                                                           Group Randomized Initial    Alcohol-Related     Psychiatric  
  Source                            Interventions          N     Desing     Abstinence Criteria            Criteria     
  Psychosocial Interventions
      Brown et al. (1997)       (T) Cognitive-             19    No         Yes        DSM-III-R           BDI<9
                                    Behavioral
                                    Therapy
                                (C) Relaxation             16
                                    training (RT)
  TCAs
      McGrath et al. (1996)     (T) Imiprimine             36                          DSM-III-R           DSM-III-R
                                    300 mg/d +                   Yes        No         Alcohol dependence  MDD, DD or
                                    relapse prevention                                                     depressive
                                (C) Placebo + relapse      33                                              disorder NOS
                                    prevention
      Mason et al. (1996)       (T) Desipramine            15    Yes        Yes        DSM-III-R           DSM-III-R
                                    200 mg/d                                           Alcohol dependence  MDD
                                (C) Placebo                13
      Nunes et al. (1993)       (T) Imiprimine             60    No         No         DSM-III-R           DSM-III-R
                                (C) No control                                         Alcohol abuse or    Major MDD or
                                                                                       dependence          Dysthymia
  SSRIs   
      Roy (1998)                (T) Sertraline             18                          DSM-III-R           DSM-III-R
                                    100 mg/d                     Yes        Yes        Alcohol dependence  MDD
                                (C) Placebo                18
      Pettinati et al. (2001)   (T) Sertraline             12                          DSM-III-R           DSM-III-R
                                    200 mg(d                     Yes        Yes        Alcohol Dependence  MDD or DD
                                (C) Placebo                17
      Gual et al. (2003)        (T) Sertraline             39                          DSM-IV              DSM-IV
                                    50-150 mg/d                  Yes        Yes        Alcohol dependence  MDD, DD or
                                (C) Plasebo                44                                              both
      Moak et al. (2003)        (T) Sertraline             38                          DSM-III-R Alcohol   DSM-III-R
                                    200 mg/d + CBT               Yes        Yes        dependence or Abuse MDD
                                (C) CBT+ placebo           44                                              or Dysthymia
      Cornelius et al. (1997)   (T) Fluoxetine             25                          DSM-III-R           DSM-III-R
                                    25 mg/d                      Yes        Yes        Alcohol dependence  MDD
                                (C) Placebo                26
      Oslin (2005)              (T) Naltrexone                   Yes        Yes        DSM-IV Alcohol
                                    (50 mg/d) + sertraline                             dependence
                                    (100 mg/d) +           37                          DSM IV
                                    supportive Therapy                                 Depressive
                                (C) Placebo +              37                          Disorder
                                    sertaline (100 mg/d) +
                                    supportive therapy
  Atypical Antidepressants 
      Roy-Byrne et al. (2000)   (T) Nefazadone             32                          DSM-III-R           DSM-III-R
                                    500 mg/d + CBT               Yes        No         Alcohol dependence  MDD
                                (C) Placebo + CBT          32
      Hernandez-Avila           (T) Nefazadone             21                          DSM-IV              DSM-IV
      et al. (2004)                 400 mg/d + supportive        Yes        Yes        Alcohol dependence  MDD
                                    psychotherapy
                                (C) Placebo +              20
                                    supportive
                                    psychotherapy
      Brown et al. (2003)       (T) Nefazadone             13                          DSM-IV              DSM-IV
                                    600 mg/d                     No         No         Alcohol dependence  MDD
                                (C) None
  Other Medications  
      Dorus et al. (1989)       (T) Lithium,               89                          DSM-III             DSM-III
                                    600   1,200 mg/d             Yes        Yes        Alcohol dependence  MDD or DD
                                (C) Placebo                82
      Salloum et al. (1998)         Naltrexone,            18                          DSM-III-R           DSM-III-R
                                    50 mg/d                      No         Yes        Alcohol dependence  MDD
                                (C) No comparison          0
                                    condition
T       Treatment Condition               C       Comparison Condition
MDD     Major Depressive Disorder         DD      Dysthymic Disorder
NC      Not calculabel                    HAM-D   Hamilton Depression scale
HAM-A   Hamilton Anxiety scale            BDI     Beck Depressive Inventory
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   Length of         Psychiatric Outcomes               Alcohol-Related   
   Experimental      Effect Sizes                       Outcomes Effect Sizes    
   Condition(s)      (Cohen’s d)                        (Cohen’s d)                       Source                        
                                                                                          Psychosocial Interventions
   8 sessions,   (1) HAM-D*                   0.69  (1) Percent days             0.59         Brown et al. (1997)  
   45 minutes    (2) POMS Depression*         1.02      abstinent
   each          (3) POMS Anxiety             0.83  (2) Drinks per day*          0.71
                                                                                          TCAs
   12 weeks      (1)  HAM-D*                  0.40  (1) % days drinking          0.08         McGrath et al. (1996) 
                                                    (2) % drinking heavily       -0.26
                                                    (3) Drinks per drinking day  0.26
   26 weeks      (1) HAM-D*                   0.93  (1) Days to relapse          0.65         Mason et al. (1996)  
   12 weeks          Of all participants,               Of 27 responsers, 18                  Nunes et al. (1993)   
                     27 (45%) were                      achieved abstinence
                     deemed "responders".               and 9 had significant
                     Mean post-treatment                reduction in alcohol use
                     HAM-D=3(+/-3).
                                                                                          SSRIs   
   6 weeks       (1) HAM-D*                   1.06      Not Tested                            Roy (1998)   
                 (2) BDI*                     0.76
   14 weeks      (1) HAM-D                    -0.21 (1) Percent Days             -0.36        Pettinati et al. (2001)  
                 (2) BDI*                     -0.20     Drinking
                                                    (2) Weeks to relapse         -0.10
   24 weeks      (1) HAM-D                    NC    (1) Days to relapse          -0.17        Gual et al. (2003)  
                 (2) SF-36 Mental             0.48  (2) Cumulative Days of       -0.04
                     Health                             Abstinence
   12 weeks          Females                        (1) Time to first heavy      0.10         Moak et al. (2003) 
                     HAM-D*                   0.76      drinking day
                     BDI*                     1.09  (2) Time to first drink      NC
                     Males                              Drinks per Drinking      0.50
                     HAM-D=3(+/-3).           0.01      Day*
                                                    (4) Percent Days
                                                        Abstinent
   12 weeks          HAM-D*                   0.57  (1) Cumulative Drinks*       0.76         Cornelius et al. (1997) 
                     BDI                      0.45  (2) Cumulative drinking      0.57
                                                        days*
                                                    (3) Drinks per drinking      0.68
                                                        day*
                                                    (4) Cumulative days          0.81
                                                        heavy drinking*
                                                    (5) # weeks to first         0.73
                                                        heavy drinking*
                                                    (6) Weeks to first drink     0.38
   12 weeks      (1) Depression               -0.09 (1) Abstinence from          -0.10        Oslin (2005)  
                     Remission (HAM-D<10)               heavy drinking*
                                                                                          Atypical Antidepressants 
   12 weeks          HAM-D (<8)*              0.71  (1) Drinks per day           0.08         Roy-Byrne et al. (2000) 
                                                    (2) Alcohol Craiving         0.38
   10 weeks      (1) HAM-D                    0.07  (1) Drinks per week*         0.82         Hernandez-Avila 
                 (2) State Anxiety            0.52  (2) Heavy drinking days*     1.01         et al. (2004)
                     Inventory
   12 weeks      (1) 45% reduction in               (1) 27.5% reduction in                    Brown et al. (2003)  
                     HAM-D scores                       Alcohol craving
                 (2) 40% reduction in               (2) 87% reduction in
                     HAM-A scores                       drinks per week
                                                    (3) 68% reduction in days
                                                        drinking per week
                                                                                          Other Medications  
   52 weeks      (1) BDI                      0.24  (1) Days drinking past       0.29         Dorus et al. (1989)
                                                        weeks
                                                    (2) Addiction Severity       -0.11
                                                        Index Global
   12 weeks          Trend in reduction of              Significant reduction in              Salloum et al. (1998)   
                     HAM-D scores (p=.078),             drinks per week and                
                     BDI scores (p=.071),               urge to drink
                     and GAF scores (p=.076)
*       Significant difference (p=<.05)
Initial Abstinence = Yes if patients were abstinent before beginning treatment.
Cohen’s d represents effect of treatment condition (T) relative to condition (C), with small, medium, and large effects defined as 0.2, 0.5, and 0.8, respectively.
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2.5 Current medical treatment of comorbid alcohol dependence
and major depression
The number of efficacy studies among comorbid alcohol dependence and major depression is
rather low, even when studies examining these separately are substantial. Studies with
tricyclic antidepressants and atypical antidepressants in the treatment of this
comorbidity have produced controversial outcomes as well as the studies with SSRIs, even
when tricyclic antidepressants tend to show better results than SSRIs (Tiet and Mausbach
2007)(Figure 2).
The current attractive medications for MDD with alcohol dependence are, however, SSRIs for
their tolerability and potential effectiveness (Cornelius et al. 1997; Cornelius et al.
2000; Nunes and Levin 2004; Roy 1998) even when some placebo controlled trials did not
provide consistent support for the use of sertraline (Gual et al. 2003; Kranzler et al.
2006; Pettinati et al. 2001) or resulted in a modest improvement at best and mainly for
women (Moak et al. 2003). The treatment of alcohol dependence comorbid with major
depressive disorder (MDD) with SSRIs, however, has generally produced positive results
(Berglund et al. 2003; Cornelius et al. 2003; Cornelius et al. 1997; Goldstein et al.
2006; Moak et al. 2003; Nunes and Levin 2004; Pettinati 2004). The treatment of this
comorbidity with serotonin and noradrenalin transporter inhibitors has produced positive
results (Hernandez-Avila et al. 2004; Yoon et al. 2006).
Nevertheless, SSRIs are safe compared to tricyclic antidepressants (TCA’s) in the
increased suicidality (Sher et al. 2005) that is comorbid with alcoholism (Pirkola et al.
2004).
2.6 Predictors for medical treatment of alcohol dependence
comorbid with major depression
The treatment of comorbid major depression and alcohol dependence is difficult and
controversial (Nunes and Levin 2006). Discontinuation of medical treatment is common
(Kranzler et al. 1996b). Predictors to antidepressant medication in treatment of
depression would be a challenge to clinicians among this group of patients (Bagby et al.
2002) The research on predictors for response to treatment in depression comorbid with
alcohol dependence is exiguous. Comorbid cocaine abuse has shown to be associated with
poorer response to antidepressant therapy for major depression comorbid with alcohol
dependence (Cornelius et al. 1998). Additional research of predictive signs in major
depression comorbid with alcohol dependence deals mainly with either one or the other
disorder.
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2.6.1 Predictors for treatment of depression
The research on the field of predictors in treatment of major depression is limited:
substance abuse has been associated with poorer response to antidepressant therapy in
depression as far as comorbidity with anxiety disorders and panic-agoraphobic spectrum
(Bagby et al. 2002). In post-stroke depressed patients the anxiousness has predicted
greater efficacy to citalopram and retarded depression to reboxetine (Rampello et al.
2004).
Early age of onset in major depression has been connected with more malignant course of
depression (Klein et al. 1999; O’Leary et al. 2000), but not with response to medical
treatment (Klein et al. 1999). Early onset of major depression has been a predictor for
personality disorders (Ramklint and Ekselius 2003) and personality disorders as predictors
has shown mainly poorer response to antidepressive treatment (Bagby et al. 2002). The
personality traits using tridimensional personality questionnaire (TPQ) are found to be
predictors to antidepressant: high harm avoidance scores have predicted lesser improvement
to treatment with antidepressants in subjects with major depressive disorder (Abrams et
al. 2004), harm avoidance scores and reward dependence scores, and their interaction were
found to predict significantly poorer response to nefazodone (Nelson and Cloninger 1997;
Nelson and Cloninger 1995).
Neurobiological factors such as dopamine impairments might have been distinguishing factor
in treatment with SSRIs (Kampf-Sherf et al. 2004), which has been indicated by correlation
on performances in neuropsychological functioning and neuromotor measures and treatment
outcomes (Caligiuri et al. 2003; Taylor et al. 2006).
2.6.2 Predictors for treatment of alcohol dependence
The predictive signs in the treatment of alcoholism have been desired for years (Naranjo
and Knoke 2001b; Pettinati and Rabinowitz 2006; Schaffer and Naranjo 1998). Prospective
studies in non-human primates that underwent early separation stress have found an
association between a low serotonin turnover rate and the disposition to excessive alcohol
intake and impulsive aggression (Heinz et al. 2001). The comorbidity with depressive
disorders, major depression (Rounsaville et al. 1987) and lifetime depression (Pettinati
et al. 2001) worsen the results of treatment in alcoholism as far as comorbidity with
anxiety disorder (Kushner et al. 2005; Willinger et al. 2002). However, comorbidity with
major depression has predicted good outcome in some studies (Johnson 2003; Johnson 2004).
In the Finnish Health 2000 study, social phobia and dysthymia were more common among
actively alcohol dependent subjects than among subjects in remission (Pirkola et al.
2006).
Personality traits such as high novelty seeking and low harm avoidance covering
exploratory excitability and impulsiveness predicted relapse (Willinger et al. 2002).
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Since Cloninger’s theory of type 1 and 2 alcoholism (Cloninger 1987), the investigation of
different pathways to indicate optimal treatment and to understand the nature of craving
has been active (Spanagel 2000; Verheul et al. 1999). Type 2 alcoholism is associated with
early onset of alcohol abuse and low 5-HIAA concentrations in cerebrospinal fluid
(Virkkunen and Linnoila 1990). This group of patients were suspected to have good response
to SSRIs, but the results were contrary (Kranzler et al. 1996a). Early onset of alcohol
problems predicted poor outcome in relapse prevention and the late onset of alcoholism
predicted better outcome to SSRIs (Chick et al. 2004; Johnson 2004; Pitkänen et al. 2005).
In treatment with naltrexone, the high baseline depression was predictive for good
treatment efficacy (Kiefer et al. 2003). Naltrexone seemed to be beneficial in the
treatment of alcoholic patients with early onset of alcohol abuse, family history of
alcoholism and comorbid use of other drugs of abuse (Rubio et al. 2005). Acamprosate was
efficacious in patients with low baseline somatic distress (Kiefer et al. 2005) but from a
pooled analysis of seven European trials, there were no predictive signs for acamprosate
treatment (Verheul et al. 2005).
2.6.3 5-hydroxy tryptamine (serotonin) transporter linked polymorphic
region (5-HTTLPR) as predictor  
One of the most important genes related to major depression is 5-HTTLPR. Serotonergic
neurotransmission is connected to both major depression and alcohol dependence (Kranzler
and Anton 1994). Serotonin neurotransmission is regulated by 5-HTT gene and the gene
expression is regulated by 5-HTTLPR polymorphism, in which the homozygosity for the long
(L) allele results in threefold higher levels of presynaptic transport of 5-HT (Heils et
al. 1996). Research to find predictive signs in serotonin transporter linked polymorphic
region (5-HTTLPR) has consistently shown the short (S) allele association with depression
but not with alcoholism (Dick et al. 2007; Marques et al. 2006; Nellissery et al. 2003).
The burgeoning evidence connects S allele concurrent with early life stress on
vulnerability to depression (Caspi et al. 2003; Dick et al. 2007; Wilhelm et al. 2006) and
early alcohol use (Kaufman et al. 2007).
Association of 5-HTTLPR gene variations with the treatment response with SSRIs in
depressed patients has shown conflicting data. Serretti found in a meta-analysis the
significant association of the L-variant of 5-HTTLPR with a better response in depressed
patients to SSRIs (Serretti et al. 2007) whereas in a recent analysis in a large clinical
sample with careful patient characterization, such association was not found (Kraft et al.
2007). Remarkably, a supportive environment appeared to protect maltreated children with
the S/S genotype from developing depression (Kaufman et al. 2004).
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3   AIMS OF THE STUDY
The aim of this study was to evaluate new treatment compound, memantine, a non-
competitive NMDA receptor blocker, for patients comorbid with major depression and alcohol
dependence and compare the results with escitalopram, a selective serotonin reuptake
inhibitor antidepressant, in a double-blind manner.
Specific aims of the study were:
1. To evaluate the influence on major depression, anxiety, cognitive functioning and
quality of life.
2. To evaluate the influence on alcohol consumption and reward.
3. To determine for the treatment of major depression, clinical and genetical predictors
of the response to both medicines.
4. To determine for the treatment of alcohol dependence, clinical and genetical predictors
of the response to both medicines.
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4   METHODS
4.1 Study participants and ethics
At three Helsinki Alcohol-clinics (A-clinics: Annankatu, Malmi and Töölö Clinics,
covering a population of about 200 000 inhabitants), men and women aged 26 to 65 years who
were voluntarily seeking outpatient treatment for alcohol problems were screened. Alcohol
dependent patients with a history of heavy drinking (five or more daily drinks for men and
four daily drinks for women) for at least ten years, and were considered to have
significant depression by the therapist and the patient (defined by Beck Depression
Inventory II (BDI-II) > 17), and who were interested in voluntarily taking part in the
study were recommended by their A-clinic doctor or social therapist to the study
physician’s interview and screening. The recruiting lasted from Dec 20, 2004 to Dec 7,
2005. For inclusion, the patients were interviewed, by a psychiatrist LM, using the
Structured Clinical Interview for DSM-IV TR (SCID), and were required to meet the criteria
of both alcohol dependence and MDD according to DSM-IV TR. Abstinence was not required,
but the time after possible prior inpatient detoxification had to be at least four weeks.
The exclusion criteria were other substance use dependence (screened by urine test), other
unstable severe mental illness (screened with the SCID), risk of suicide, pregnancy or
breastfeeding, a severe untreated somatic problem, or a serious dysfunction of liver
(aspartate aminotransferase [AST] and alanine aminotransferase [ALT] > 200), mental
disability and incarceration. Other medications prescribed by their physician were
allowed, with the exception of other antidepressants.
The study was approved by the independent Hospital District of Helsinki and Uusimaa,
Ethical Committee (permission 22/2004) and the Finnish National Agency of Medicine (KL#
87/2004). The study was conducted according the International Conference on Harmonisation
(ICH) guidelines for Good Clinical Practice and the 1964 Declaration of Helsinki. The
study was registered on the National Public Health study registry in March 2005 (172-9)
and the ClinicalTrials.gov Identifier (trial # NCT00368862). Separate informed consent for
the DNA test for 5-HTTLPR allele variation was approved Hospital District of Helsinki and
Uusimaa, Ethical Committee (permission to amendments 9.5.2006 and 29.4.2008). All patients
had to be able to read and understand the patient information sheet and sign the informed
consent. All participants were free to stop study medication whenever they wanted. The
patients were not paid or reimbursed for participation.
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4.2 Study medication
4.2.1 Memantine
Memantine is a non-competitive N-methyl-D-aspartate (NMDA) ionotropic glutamate receptor
blocker. In addition, it inhibits 5-Hydroxy tryptamine 3-receptors, which may contribute
to its therapeutic efficacy (Johnson and Kotermanski 2006). It has also some antagonism on
nicotinic acetylcholine receptors (Parsons et al. 1999). It is approved for the treatment
of moderate to severe Alzheimer disease (Gortelmeyer and Erbler 1992; Johnson and
Kotermanski 2006), with no clear benefit to date for mild stages of Alzheimer’s disease or
for vascular dementia (Muir 2006). It may have some effect on alcohol related dementia
(Cheon et al. 2008). In a preclinical study, memantine seems to have anxiolytic response
(Minkeviciene et al. 2008).
A research with memantine in the field of neurodegenerative diseases like glaucoma (Levin
and Peeples 2008), amyotrophic lateral sclerososis (Lou Gehrig’s disease), Parkinson’s
disease and neuropathic pain (Planells-Cases et al. 2006) is in progress.
It is efficient in treatment of Huntington’s disease (Beister et al. 2004). An additional
finding is that memantine may have therapeutic potential for tinnitus (Figueiredo et al.
2008; Lobarinas et al. 2006), migraine (Charles et al. 2007; Peeters et al. 2007) and
binge eating disorder (Brennan et al. 2008).
Memantine seems not to have abuse liability in cocaine dependent rats (Hyytiä et al. 1999)
or humans (Vosburg et al. 2005).
4.2.2 Escitalopram
The SSRI used in the present study is escitalopram, the active S-enantiomer of the racemic
selective serotonin reuptake inhibitor citalopram. It is a highly selective inhibitor of
the serotonin transporter protein (Murdoch and Keam 2005). There is evidence that
citalopram is an effective antidepressant in various controlled clinical trials (Pollock
2001). The escitalopram shows better efficacy and higher rates of response than the
racemic compound (Owens et al. 2001; Sanchez et al. 2004).
In addition, escitalopram is indicated in generalized anxiety disorder (Varia and Rauscher
2002), social anxiety (Varia et al. 2002), panic disorder (Stahl et al. 2003) and
obsessive-compulsive disorder (Stein et al. 2007).
Escitalopram has been investigated in posttraumatic stress disorder with good results
(Robert et al. 2006) as well as gambling (Grant et al. 2006).
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4.3 Study design
Study enrollment began on December 20, 2004, and the last patient completed the study on
May 25, 2006. The same study physician (LM) screened, enrolled, and treated all patients.
After providing initial examination, patients underwent procedures including the recording
of demographic and medical history, physical examination, laboratory examinations (urine
drug screen, serum AST, ALT, desialotransferrine (CDT), gamma-glutamyltransferase (GGT),
tyreotropine, creatine, sodium and potassium) with the analysis performed by the
independent accredited VITA-terveyspalvelut Ltd, Helsinki, Finland, a screening interview
(SCID (First et al. 1995)) to provide a detailed diagnostic characterization of mental and
alcohol problems of the patients, and interviews for the Montgomery-Åsberg Depression
Rating Scale (MADRS (Montgomery and Asberg 1979)), the Hamilton Anxiety Scale
(HAM-A (Hamilton 1959)), the Social and Occupational Functioning Assessment Scale
(SOFAS (Goldman et al. 1992)) and the Consortium to Establish a Registry for Alzheimer
Disease cognitive test battery (CERAD (Fillenbaum et al. 1997)). A set of questionnaires
were filled in by the patients, including: Tridimensional Personality Questionnaire (TPQ
(Cloninger 1987)), Beck Depression Inventory II (BDI-II (Beck et al. 1996)), Beck Anxiety
Inventory (BAI (Beck et al. 1988)), Alcohol Use Disorders Identification Test (AUDIT
(Saunders et al. 1993)), Obsessive Compulsive Drinking Scale (OCDS (Anton 2000)) and
Visual Analogue Scale (VAS (Nord 1991; Scott and Huskisson 1976)). In addition, The
European Quality of life, 5 items (EQ5) (EuroQol Group 1990) and Koskenvuo items for
quality of life (Koskenvuo 1979) were permitted. The quantification of alcohol
consumption and study medication during the 26 week treatment period was assessed by
Drinking Diary (Poikolainen and Kärkkäinen 1983), AUDIT QF (Aalto et al. 2006) and
AUDIT 3 (Gual et al. 2002).
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Figure 3. Study CONSORT Flowchart. 
                                     Initial assesment for
                                     screening eligibility
                                     (all A-Clinic patients,
                                     population unknown)
                                     Assessed for eligibility
                                     (N=89)
                                                                       Excluded (N=9)
                                             Enrollment                Not meeting inclusion
                                                                       criteria (N=3)
                                                                       Refused to participate (N=5)
                                                                       Other reasons (N=1)
                                        Randomized (N=80)
            Memantine                                                       Escitalopram
  Allocated to intervention                                         Allocated to intervention
  (N=40)                                                            (N=40)
  Received allocated                                                Received allocated
  intervention (N=40)                       Allocation              intervention (N=40)
  Did not receive allocated                                         Did not receive allocated
  intervention (N=0)                                                intervention (N=0)
  Lost to follow-up (N=3)                                           Lost to follow-up (N=4)
  3 for unknown reasons                                             4 for unknown reasons
  Discontinued intervention (N=8)                                    Discontinued intervention (N=7)
  1 sudden death,                           Follow-Up               1 sudden death,
  4 adverse events,                                                 3 adverse events,
  1 protocol violence,                                              2 protocol violence,
  2 poor compliance                                                 1 poor compliance
  Completers (N=29)                          Analysis               Completers (N=29)
  Excluded from analysis (N=0)                                      Excluded from analysis (N=0)
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All patients meeting the inclusion criteria were randomly assigned by an independent
person (S. Päivinen) to memantine or escitalopram groups using 1:1 ratio (N=40 + 40) and
random permuted blocks (Vassar Statistic randomizing algorithm). The sample size was
defined by dichotomous power analysis in which α=0. 05, β=0. 10, f(αβ)=10,5 , p1=10,
p2=40 and n=p1 x (100-p1) + p2 x (100-p2) / (p2-p1) x 10.5=38, to control
the dropouts the sample size in each group is 40. The randomization was concealed until
the study database was locked (MedFiles Ltd, June 6, 2006). In an emergency or in a case
of Serious adverse event (SAE) an individual random number could be opened by an
independent person. The study medication (kindly provided by Lundbeck Oy Ab, Turku,
Finland) was double-dummy packed: the patients took two pills every time, one of which was
the active medicine and the other identical placebo for the second medication. The
medication was labeled and controlled by an independent supplier (Pharmia Ltd., Seinäjoki,
Finland). Eligible patients were randomly allocated to receive either 20 mg /day
escitalopram or 20 mg/day memantine. The starting dose was 5 mg for both drugs, and was
increased at weekly intervals by 5 mg/day to 20 mg/day. After four weeks, the study
physician was allowed to decrease the dose if a patient could not tolerate the medication.
Patients were instructed to take the study medication in the morning. Other than
antidepressive drugs, concomitant medication was allowed during the study. There were no
additional psychosocial interventions by the study physician. Concomitant intervention on
alcohol consumption was not done, and no treatment goals were imposed. Patients were
permitted to telephone the study physician at any time. If the patient did not appear at a
scheduled visit, a new appointment was offered.
During the 26 week treatment period, the patients returned to the A-clinic at weeks 1, 2,
4, 12±2 and 26±2 for data collection and for medication checking and dispensing. At weeks
18-20, a 10-15 minute phone conversation with each patient was made. At each visit, the
study medication intake since the previous visit was recorded using the drinking diary.
The study medication was ensured with the pill count from the returned baggage. Any
possible adverse events were elicited by the study physician at each visit and recorded by
the patient to drinking diary. Other measures were recorded on specific weeks: MADRS,
HAM-A, SOFAS, BDI-II, BAI, OCDS, EQ-5, Koskenvuo life scale and VAS (0, 4, 12 and 26
week); AUDIT (0 week) and AUDIT 2 (12 and 26 week) modified to report events in the
previous month; TPQ and CERAD (0 and 26 week). Clinical laboratory tests (Mean corpuscle
volume [MCV], CDT, Blood ASAT, ALAT, CDT, and GGT) were taken in the beginning of
research and were repeated at weeks 4, 12 and 26 to ensure the safety of medication.
The study was monitored by an independent organization Medikalla Oy, Medfiles, Turku.
For the outcome association analysis the patients in both medication groups that completed
the study were divided twice in two subgroups. The first division was for predictors in
treatment of depression: remitted patients were those who had at the end of study MADRS
scores ≤12 and non-responders were those of the rest who had reduction of MADRS scores
<50% (Montgomery et al. 1993). MADRS was analyzed in total score and in dimensions of a
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three-factor analytic model (Parker et al. 2003). The second division was for predictors
in treatment of alcohol dependence: those who received AUDIT-points <8 constituted the
group of remission and those with AUDIT-points ≥20 constituted the group of non-
responders, according to World Health Organization (WHO) distribution (Babor and World
Health Organization. Dept. of Mental Health and Substance Dependence. 2001). All baseline
and demographic data was analyzed with these distributions.
All primary and secondary outcome statistical analysis was performed by independent source
(Medikalla Oy, MedFiles, Turku).
Figure 4. Study Investigation Flowchart.
        *                               **
-1      0       1 wk       2 wk         1 mo          3 mo         4.5 mo            6 mo
R       D       D          D            D             D            PC                D
        LAB                             Lab           LAB                            LAB
        +TSH, Na , K,
        S, SCID
        M+Cerad,  TPQ                    M             M             BDI              M, Cerad, TPQ
                                        (not AUDIT)                 BAI
R       =       Recruiting patients, patient information, inclusion/exclusion criteria
D       =       Doctor’s visit
PC      =       Phone contact
LAB     =       Blood Count, CDT, ASAT, ALAT, GGT, Crea
Lab     =       Crea, ASAT, ALAT, GGT, Na, K
S       =       Status and demographic data
SCID    =       Check the criteria for alcohol dependence and major depression with SCID
M       =       Study outcome measures: AUDIT, BDI-II, BAI,  MADRS, HAM-A (Hamilton Anxiety),
                EQ-5, Koskenvuo life scale, VAS, drinking diary
BDI     =       BDI-II (Beck depression inventory, sent to patients)
BAI     =       (Beck Anxiety Inventory, sent to patients)
*       =       informed consent, randomization, start of the medication (25% of the final dose)
**      =       medication 100 %
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4.4 Statistical analysis
Statistical evaluation utilized Statistical Analysis Software (SAS) Procedures in SAS
system for Windows (Version 8.2), SAS-institute, Finland. The intent-to-treat population,
which included all randomized patients including two early terminating patients who
reported taking no medication, were used in all tables and analyses. Descriptive
statistics were calculated for all variables. Categorical variables were presented in
frequencies tables (PROG FREQ in SAS) (number of cases and percentages) by treatment.
The numerical variables were tabulated by treatment (PROG UNIVARIATE in SAS).
Baseline measures were analyzed by logistics regression or analysis of variance. MADRS,
BDI-II, HAM-A, BAI, CERAD, AUDIT and OCDS were all analyzed with analysis of
variance (ANOVA) for repeated measures when treatment, time (0,4,12 and 26
weeks) and treatment*time interaction were in the model (PROG MIXED in SAS) and
responses to specific question ("Has your depression or drinking declined during
the study?") were analyzed by logistic regression (PROG LOGISTIC in SAS). The modeling
of associations between genotype and MADRS score decrease and genotype and AUDIT score
decrease was carried out with linear regression separately in both medication groups.
First "LL" genotype was compared to other genotypes, then linear trend in respect to
number of "L" alleles (0, 1, or 2) was checked. Linear trend was tested with likelihood
ratio statistics.
Differences in baseline characteristics for the four groups (memantine in remission / non-
responders and escitalopram in remission / non-responders) were analyzed with analysis
of variance, analysis of covariance and multiple linear regression analyses. Moreover,
Spearman’s correlations were calculated between variables by treatment group. Differences
between correlations in memantine and escitalopram groups when measured with MADRS,
were analyzed with Z statistics (Hays 1963).
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5   RESULTS
Out of those eighty-nine patients, who were initially screened from patients of the
Helsinki A-clinic, three were excluded because they did not meet inclusion criteria, five
refused to participate and one did not return after pre-screening. Eighty patients were
randomized to either memantine or escitalopram (N=40 + 40). Blinding was assured by a
double-dummy design. The patients were aged 26 to 65 years, and 55% were men. There were
no significant differences between groups in their demographic characteristics in the
initial alcohol and depressive measures. The mean length of the present depressive period
was 35 months. Active alcohol abuse was reported by seventeen patients in both groups.
Abstinence of one to three months was reported in the memantine group by 17 patients and
in the escitalopram group by 18 patients. Abstinence up to one year was reported by five
patients in both groups. (Data is missing for one memantine-randomized patient due to an
interrupted interview.) The number of study patients’ treatment visits in A-clinics during
the study period was similar (in memantine group 7.7, Standard Deviation (SD)±8.8 and in
escitalopram group 7.1, SD±9.8).
The completion rate of the 26 week study period was identical in both groups: 72.5% (29)
for memantine and 72.5 % (29) for escitalopram (Table 2). The reasons for discontinuing
the study were: adverse events (memantine 5, escitalopram 4), protocol violations
(memantine 1, escitalopram 2), poor compliance (memantine 2, escitalopram 1), and loss to
follow up for unknown reasons (memantine 3, escitalopram 4). All of the 58 subjects who
completed the study attended all appointments and showed at least 80 % compliance based on
tablet counts.
The average consumption (mg) of medication did not differ between the two medication
groups: during the first 12 weeks, 17.4±2.8 mg for memantine, (mean±SD) and 16.9±3.6
mg for escitalopram; and for weeks 13-26, 17.4±3.2 mg 26 for memantine and 15.9±4.4 mg
for escitalopram.
5.1 Major depression, anxiety, cognition and quality of life
5.1.1 Major depression
The depressive symptoms measured by MADRS decreased significantly from baseline in the
memantine group from 25.8±4.4 to 12.7±7.0 and in the escitalopram group from 26.8±4.1
to 11.5±6.6 (F[3,77]=138.04, p<.0001), with no significant differences between the two
treatment groups (F[3,77]=1.13, p=0.94). In memantine group, 17/29 patients reached
remission and 11/29 were non-responders. In escitalopram group, 17/29 patients reached
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remission (MADRS ≤12) and 9/29 patients were non-responders (MADRS decrease <50%).
One patient in escitalopram group and three patients in memantine group received
MADRS decrease > 50 % but remained still >12 scores. On the baseline demographic data
there were no differences between the age and gender in these four groups.
The self-rated depression scores (BDI-II) also decreased from baseline in both groups: in
the memantine group from 27.7 (±8.4) to 15.3 (±11.1) and in the escitalopram group from
27.6 (±6.8) to 14.3 (±11.8) (F[4,77]=25.77, p<.0001); there was no difference between
the two treatment groups (F[4,77]=0.92, p=0.68). In memantine group, 17 patients reached
BDI scores ≤ 15 and 12 of them ≤10. In escitalopram group, 21 patients reached BDI scores
≤15 and 17 of them ≤10.
When questioned at the end of the intervention, 75.9 % of patients in the memantine group
and 72.4 % of patients in the escitalopram group reported their depression to be
decreased.
5.1.2 Anxiety
Anxiety symptoms, measured by HAM-A, decreased significantly from baseline in the
memantine group from 17.1±4.7 to 7.8±4.3 and in the escitalopram group from 18.1±4.4 to
7.9±5.5. (F[3,77]=132.14, p<.0001) with no significant difference between the two
treatment groups (F[3,77]=0.38, p=0.5). The self-rated anxiety scores (BAI) decreased in
the memantine group from 21.5±11.7 to 12.6±10.2 and in the escitalopram group from 20.2
±9.3 to 13.6±14.9 (F[4,77]=6.45, p=0.0002). There was no significant difference or
interaction between the two treatment groups (F[4,77]=1.31, p=0.27) (Fig.3).
5.1.3 Cognitive functioning
The cognitive performance scores (CERAD) did not change significantly during the study
period in either treatment group. They were already at baseline in the range of the
reference values. The mean Mini Mental State Examination (MMSE) score at baseline was in
memantine group 28.1±1.4 and in escitalopram group 28.0±1.7, and at the end of the study
in memantine group 27.9±1.5 and in escitalopram group 27.4±1.5. (F[1,77]=3.1, p=0.08).
The average retrieval percentage of wordlist at baseline was in memantine group 89.2±16.8
and in escitalopram group 83.9±19.5 ,and at the end of the study in memantine group 88.1
±16.5 and in escitalopram group 89.9±13.5 (F[1,77]=1.21, p=0.28).
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5.1.4 Quality of life
The quality of life, estimated using the Visual Analogue Scale (VAS) score, increased in
both treatment groups. In the memantine group, it increased from 39.7±19.3 to 54.6±20.8
and in the escitalopram group from 40.5±16.5 to 56.6±23.2 (F[3,77]=10.27, p<.0001).
There was no statistical difference between the two groups (F[3,77]=0.25, p=0.9). Scores
on the social and occupational functioning scale, SOFAS, increased significantly in the
memantine group from 52.7±9.2 to 67.2±11.7 and in the escitalopram group from 53.2±9.9
to 63.8±11.4 (F[3,77]=39.75, p<.0001)). There was no significant difference between the
groups (F[3,77]=1.7, p=0.86).
5.2 Alcohol consumption and craving
5.2.1 Alcohol consumption
The AUDIT scores decreased from baseline in both groups, from 27.4±7.1 to 14.3±9.9 in
the memantine group and from 28.4±1.0 to 17.6±1.9 in the escitalopram group. The overall
reduction was highly significant (F[2,77]=48.42, p<.0001). There was a non-significant
tendency for lower AUDIT scores in the memantine group than in escitalopram group
(F[1,77]=2.82, p=0.10). The treatment by time interaction was not significant
(F[2,77]=1.19, p=0.31).
Alcohol consumption measured by the AUDIT QF (quantity-frequency) score was significantly
reduced in both groups: in the memantine group from 6.2±1.7 to 4.1±2.5 and in the
escitalopram group from 6.1±1.7 to 4.3±2.3 (F[2,77]=23.53, p<.0001. The number of heavy
drinking days measured by the AUDIT 3 score was also diminished significantly in both
groups: for memantine from 2.9±1.1 to 1.8±1.3 and for escitalopram from 3.1±1.0 to 2.4
±1.3; (F[2,77]=20.29, p<.0001. The difference between the groups approached significance
with the memantine group doing slightly better (F[2,77]=1,37, p=0.067).
The number of abstinent days per week was high for both groups throughout the study. In
weeks 14, 16, 18, and 25, the memantine group had significantly more abstinent days than
the escitalopram group (p<0.05). The treatment by time interaction throughout the study
was not significant (F[2,74]=0.07, p=0.92). The mean alcohol intake was 15.0±2.6g per
day for the memantine group and 21.1±3.6g per day for the patients on escitalopram, with
no significant difference between the groups (F[1,74]=1.94, p=0.17).
When questioned at the end of the intervention, 68.9% of patients in the memantine group
and 62.1% of patients in the escitalopram group reported their alcohol use had decreased.
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5.2.2 Alcohol craving
The OCDS total scores decreased in the memantine group 18.8±6.9 to 10.6±7.2 and in the
escitalopram group from 20.4±4.9 to 12.8±8.6. The overall reduction was highly
significant overall (F[3,77]=25.76, p<.0001). The interaction was not significant
(F[3,77]=0.69, p=0.56). There was a trend for the memantine scores to be lower than those
for escitalopram (F[1,77]=3.30, p=0.073). The scores were significantly lower in the
memantine group than the escitalopram group at the 1 month visit (F[1,72]=6.53, p=0.013.
The final scores were below 5 in 51% of the memantine patients but only 27% of the
escitalopram patients.
The OCDS subscale scores related to the Obsessive Thoughts of Drinking decreased
significantly (F[3,77]=23.11, p <.0001) in both groups: in the memantine group from 7.9
±3.4 to 4.2±3.2 and in the escitalopram group from 8.9±2.4 to 5.3±4.2. These subscale
values were significantly lower in the memantine than escitalopram subjects at the 1 month
visit (F[1, 72]=5.85, p=0.018.
The OCDS Compulsive Drinking subscale also decreased significantly (F[3,77=18.19, p<.0001)
in both groups: the decrease was from 10.9±4.0 to 6.4±4.6 in memantine group and it was
11.5±3.3 to 7.5±4.9 in escitalopram group. The score in the memantine group was
significantly lower than that in the escitalopram group at 1 month (F[1,72]=4.62,
p=0.035).
In both groups the mean serum concentration of ASAT, ALAT, GGT and CDT were within
normal limits. There were no significant changes during the treatment period nor any
significant difference between groups.
5.3 The comparison between recovery in depression and alcohol use
The analysis between the MADRS scores decrease and the AUDIT scores decrease showed
difference in correlations : in memantine group there was a non-significant correlation
(p=0.12), whereas in escitalopram group the correlation was significant (p=0.025). The
data is based on an article containing the decrease in alcohol use (Muhonen et al. 2008a)
and an article containing the decrease in depression and anxiety scores (Muhonen et al.
2008b).
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Figure 5. Correlation between MADRS scores decrease and AUDIT scores at the end of the    
study, significant correlation in escitalopram group (p=0.025) unpublished. 
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5.4 Predictors for treatment of depression
Twenty-nine patients of forty (72.5%) completed the 26 weeks study period in both
treatment group with either escitalopram or memantine.
5.4.1 Escitalopram group
In the escitalopram group the mean age at onset of major depression was significantly
different between remitted and non-responding patients, 31.9±11.9 years (mean±SD) for
remitted and 13.7±4.0 years for the non-responders (t[24]=4.42, p=0.00018). However,
there was no difference in duration of current actual depressive episode 51.0±57.7 months
in remission group and 65.3±110.6 months in non-responders group. The onset of the first
depressive episode over the age of 20 years was associated to good treatment outcome
(p<0.005): all of these patients reached remission in escitalopram group. All
non-responding patients in escitalopram group had the first episode of depression before
the alcohol dependency.
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It was further tested with multiple linear regression whether age of onset of depression
predicted change in MADRS when the scores were treated as continuous variables. Indeed,
after controlling for the MADRS score in the baseline, earlier age of onset predicted
higher MADRS score at six months in the escitalopram group (B=-0.30, 95% CI=-0.47 to
-0.13, p=0.001). Further adjusting for gender and age did not alter the significance
level. The family history of alcoholism did not correlate to the treatment outcomes, among
the patients without family history of alcoholism three were in non-responder group and
four in responder group.
In the three-factor analytic model of MADRS, the mean values of "psychic anxiety"
dimension (questions 3, 9 and 10 of inner tension, pessimistic thoughts and suicidal
thought) were more frequent in non-responders (9.1±2.4) than in remitted patients (7.2
±1.6) (p<0.05).
The analysis of the Tridimensional Personality Questionnaire (TPQ), the signs of pessimism
(p=0.05) and impulsiveness (p=0.09) were associated with poor outcome.
5.4.2 Memantine group
In memantine group, there were no differences in the age at onset of depression between
remission group (28.4±13.5 months) and non-responders group (26.5±12.3 months). Among
those of memantine group who had their first depressive episode under the age 20, six of
ten patients received remission. The actual depressive episode had lasted in memantine
remission group 16.1±25.3 years and non-responders group 21.6±33.4 years with no
difference between the outcome groups. The onset of the first depressive episode was not
associated to treatment outcome (t[26]=0.37, p=0.71). All patients without family history
of alcoholism received remission and were associated to good treatment outcome (p<0.05).
In baseline MADRS value, in remitted patients group the mean was 23.5±3.2 and in
non-responders 27.4±4.7 (p=0.02) predicting better outcome in lower baseline values. In
the three-factor analytic model of MADRS, there were no differences between the mean
values of non-responders and remitted patients in any dimensions.
In TPQ, the signs of pessimism and impulsiveness were not associated with treatment
outcome in memantine group.
In both treatment groups, there was no difference between the baseline alcohol consumption
and dependence measures (AUDIT, OCDS) abstinent days, onset of drinking and alcohol
dependency.
45
Figure 6. Correlation between the age at onset of the first depressive episode of major  
depression and the efficacy of memantine and escitalopram.  
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Efficacy was measured as the decrease in MADRS from baseline to the end of the study (26
weeks). A highly significant correlation (p < 0.0001) was found with escitalopram but not
with memantine. The difference between the two correlations was significant ( Z=3.7254,
p=0.0002).
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5.5 Predictors for treatment of alcohol dependence
5.5.1 Escitalopram
In escitalopram group, 9 patients reached AUDIT <8 scores and 12 patients AUDIT scores
>20. In memantine group, 9 patients reached AUDIT scores <8 and 9 patients over 20.
In escitalopram group, there was significant difference in demographic backgrounds on the
age of the first alcohol intoxication, the mean age of the first intoxication was in
non-responders group 14.6±1.4 years and in responders group 17.3±3.4 years (p=0.04). The
similar difference was in the age of the first depressive episode: the mean age was in
non-responders 20.4±8.3 years and in responders group 33.5±15.8 years (p=0.03). In
multivariant analysis, the age in the first depressive episode explained the first
intoxicative drinking significantly (p<0.05) but not vice versa.
5.5.2 Memantine
In memantine group, the mean age at the time of the first alcohol intoxication was in
non-responders group 15.0±3.6 years and in responders group 16.1±2.5 years (p=0.39).The
mean age in the time of the onset of first depressive episode was in non-responders group
28.1±16.9 years and in responders group 31.1±8.8 years (p=0.74).
5.5.3 Baseline alcohol use
In either group, there were no differences in mean ages in times of regular use of alcohol
or alcohol dependence. The previous time of abstinence was not predictive, but those
patients who were abstinent at the beginning of treatment were more likely to complete the
treatment than those who were still drinking at the beginning (χ2=6.51, df=1, p=0.011).
This relationship was highly significant in the patients treated with memantine (χ2=7.25,
df=1, p=0.007): 8 of the 10 who dropped out were among the 17 (47.1 %) who were active
drinkers at the baseline. The relationship was in the same direction in the escitalopram
group but failed to reach statistical significance (χ2=0.901, df=1, p=0.343). There was no
significant difference between the memantine and escitalopram groups in this relationship
between abstinence or drinking at the onset of treatment and the likelihood of dropping
out (χ2=1.864, df=3, p=0.601).
The baseline scores in AUDIT, OCDS and its subgroups were not predictive nor the baseline
scores in other psychiatric measures.
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5.6 Comparison between predictors in depression and alcohol use
In MADRS decrease, when compaired to onset of the first depressive episode and the first
intoxicative drinking, there was no correlation in non-responders group with either
medicines, whereas in responders group there were slight correlation with escitalopram
(p=0.05) and remarkable correlation in memantine group (p=0.004).
In AUDIT decrease, when compaired to the onset of the first depressive episode and the
first intoxicative drinking, there was no correlation in escitalopram non-responders
group and a slight correlation (p=0.03) in memantine non-responders group. In responders
group there were correlation between the age in the first depressive episode and the first
alcohol intoxication in escitalopram group (p=0.013) but no correlation in memantine
group.
5.7  5-HTTLPR polymorphism as a predictor 
Of the 40 patients receiving escitalopram treatment, 11 dropped out. Of the patients
finishing the trial, 20 patients received MADRS decrease ≥50% and 9 patients <50%. In the
group responding to escitalopram treatment (N=20), 11 patients carried the LL genotype, 6
patients had the SL genotype and only one the SS genotype. Two patients did not sign the
informed consent. The prevalence of the L-allele was consequently 78% and the prevalence
of the S-allele 22%. In contrast, in the group of non-responders (N=9), there were only
two patients with the LL genotype, six individuals carried the SL genotype and one the SS
genotype. The frequencies of the L- and S-alleles were thus 55% and 45%, respectively.
When the response to the treatment was compared to the genotype by using linear
regression, it was observed that the decrease in MADRS scores was significantly associated
with LL genotype (F=5.46, p=0.028), the decrease was higher, mean difference being 20%,
(95% CI: 2.2 to 37) in LL group compared to other genotypes. Also detected was linear
trend in respect to number of L-alleles (F=4.64, p=0.04); having one L-allele more
predicted 15% (95% CI: 0.6 to 29) unit decrease in MADRS score. In similar analysis no
association between AUDIT and genotype was detected (F=0.23, p=0.64).
Of the 40 patients receiving memantine treatment, 11 dropped out. Of the patients
finishing the trial, 16 patients received MADRS decrease ≥50% and 13 patients <50%. In
the group responding to memantine treatment, 2 patients carried the LL genotype, 7
patients had the SL genotype and 2 the SS genotype. Five patients did not sign the
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informed consent. The frequencies for both alleles were 50%. In the group of
non-responders, 2 patients carried the LL genotype, 5 patients had the SL genotype and 3
the SS genotype. Three patients did not sign the informed consent. The frequencies for L-
and S-alleles were 55% and 45%, respectively.
Using linear regression, there was no association with MADRS scores (F=0.02, p=0.90)
and AUDIT scores (F=0.01, p=0.91) decreases and genotype in memantine group.
5.8 Safety and tolerability
During the half year study period, seven patients discontinued treatment due to adverse
events, four in the memantine group and three in the escitalopram group.
In the memantine group, one patient was withdrawn due to eczema and three because of
labile mood and depression. In the escitalopram group, one patient was withdrawn due to
disorientation after the first day on medication, and two because of labile mood and/or
depression. The majority of the patients ( 90 % in the memantine group and 97% in the
escitalopram group) reported at least one adverse event (AE) during the 26-week study
period. The most common adverse event was somnolence (memantine 36 % and escitalopram
34 %) and headache (memantine 36 % and escitalopram 29%). There was no significant
difference in the incidence of adverse events between the two treatment groups.
Values for the clinical laboratory tests were in the normal range at the beginning
and the end of the study.
Serious adverse events were reported by three patients (two memantine and one
escitalopram), one suicide attempt in the memantine group and two sudden deaths (one due
to hyperglycemia in the memantine group and one due to intoxication of street drugs in the
escitalopram group).
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6   DISCUSSION
6.1 Purposes of the study
The most eager aim of the study was to find out some new alternatives in the treatment of
comorbid alcohol dependence and major depression. The importance of treatment studies in
this comorbidity is in agreement with a novel finding of high level of childhood depressed
mood association with earlier onset of alcohol problems (Crum et al. 2008).
Another aim was to detect some predictive signs for clinician when making decisions of
medical treatment for this comorbidity. This study of treatment on alcohol dependence
comorbid with major depression was a randomized comparison of two differently acting
compounds, memantine, a non-competitive antagonist of glutamate NMDA receptor, and
escitalopram, a selective serotonin reuptake inhibitor, in a double-blind manner. The
patients for this study were recruited from three municipal A-clinics in Helsinki. The
trial lasted 26 weeks.
6.2 Diagnostical considerations
The patients for this study were sent by nursing staff from communal alcohol-clinics. Out
of the total sample of alcohol dependent patients, those patients who were noticed to have
comorbid long-lasting severe depression were asked to meet study physician for detailed
diagnostical interview by SCID (TR). The problem in this study was the definition of MDD
comorbid with alcohol dependence. It is often assumed that MDD after alcohol dependence
is secondary and caused by drinking, but there are several factors contributing to the
confusion between alcoholism and affective disorders (Schuckit 1986). The truth is that we
cannot be sure of the connection between these. Even when the mood is depressive in the
time of withdrawal symptoms, we cannot know if the later depression is caused by
alcoholism. They may have a relationship to each other or they may be independent diseases
with some overlap in clinical symptoms. They may be originally consequences of the same
origin, e.g. chronic stress or glucocorticoid exposure (Board et al. 1956; Jezova 2005;
Wong et al. 2008). Distinguishing between primary and secondary depression among patients,
and questions about whether alcoholism causes depression or depression causes alcoholism,
or are they independent of each other, remain unanswered. The interaction between
alcoholism and major depression needs further investigation.
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6.3 Methodological considerations
6.3.1 Rating scales
In addition to recording of demographic and medical history, several different
questionnaires and rating scales validated in Finland were fulfilled by the patients
(BDI-II, BAI, VAS, EQ-5, Koskenvuo items for quality of life, AUDIT, OCDS, Drinking Diary
and TPQ) and the study physician (MADRS, HAM-A; SOFAS and CERAD).
Almost all the scales proved to be useful in the study. The BDI-II scales reduction was
analogous with those of MADRS and the BAI scales reduction was similar to those of HAM-A.
Of quality of life scales, the VAS and the SOFAS scales gave the most valuable
information. The EQ scale did not confront the study patients’ problems and the Koskenvuo
life chart did not add new information.
The measurement of alcohol dependence was problematic. The AUDIT and OCDS tests gave
similar results for patients. Whereas the focus of AUDIT was in drinking patterns, the
focus of OCDS was both in drinking patterns and in thoughts of drinking and gave more
valuable information. The rating of this OCDS questionnaire, however, is too complicated
to use in a normal clinical setting.
Conclusions from the drinking diary results were limited by the lack of baseline data
before treatment for abstinent days, heavy drinking days and alcohol consumption, so
whether the relative high number of abstinence days throughout the treatment period is
actually different from those before treatment, remains unproved.
The TPQ test was useful, but it is not suitable for a normal clinical appraisal. It would
be beneficial to establish a simple questionnaire for a clinician to detect personal
styles of a patient.
CERAD test battery was chosen because it can easily be used by others rather than just
psychologists and contains several parts assessing episodic memory. This can be impaired
in alcoholics especially due to B1-vitamin deficiency (Korsakoff’s syndrome), but also
milder memory deficits can be seen in heavy drinkers (Parsons 1998). CERAD test battery
seemed not to be sensitive enough to recognize cognitive impairment in this group of
patients.
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6.3.2 Cohort sample
The sample size of study patients was defined by dichotomous power analysis. The dropout
ratio was somewhat lower than expected, only 27.5% compaired to nearly 40% described in
literature (Kranzler et al. 1996b). The naturalistic character of the study (random sample
of A-clinic outpatients) increases the applicability to clinical practice. The
sociodemographic indicators correspond well to those generally found among patients
treated at Finnish A-Clinics (Heinälä et al. 2001), suggesting the present material
represents a relatively unbiased sample. The only difference observed was the higher
percentage of women that can probably be attributed to the inclusion criteria of major
depression.
6.3.3 Medicines
One basis for the study was the different transmitter action in brains between the study
medicines. The other was a SSRI, escitalopram, as an active comparator and another was an
uncompetitive glutamate antagonist, memantine, as an investigated medicine. There are,
however, some pharmacological differences between individual SSRIs, citalopram and
escitalopram being the most selective 5-HT reuptake inhibitors within this class of drugs
(Carrasco and Sandner 2005) and, in addition, the differences between effects on dopamine
D2 receptors (Penttila et al. 2004). In addition, it is possible that the action of both
medicines, esitalopram and memantine, is based on the Hypothalamus-Pituitary-Adrenal (HPA)
axis dysregulation, which is assumed to be a link between serotonin deficiency and
increased glutamate activity in depression (Muller and Schwarz 2007). In addition, HPA is
connected with both transmitters with alcoholism (Jezova 2005; Sher 2007). Concomitant
medication, exept antidepressants, was allowed during the study. One third of the patients
reported to use other psychiatric medication in the beginning of the study. The medication
was asked with a self-rating questionnaire, so as not to separate tranquilizers and
anti-psychotics. The definition of policy to bentzodiatsepines in A-clinics is, however,
rather critical, and the use of them in this study was presumably insignificant.
6.3.4 Safety and tolerability
The amount of adverse events were somewhat higher in this study than they have been in
producer’s information. The mortality is equal with the average mortality in this group of
patients in Finland (Mäkelä and Saarnio 1997). These events were considered by the study
coordinator (HA) not to be related to the study treatment based on clinical evaluation and
forensic autopsy reports for each case.
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6.4 Main findings
6.4.1 Depression and anxiety
Symptoms of depression and anxiety outcomes significantly improved in both treatment
groups. The decrease in depressive symptoms in the escitalopram group in this study was
consistent with conclusions from a recent review supporting SSRI treatment in depression
with comorbid substance use disorders (Nunes and Levin 2004). The assumption that
memantine, a non-competitive glutamate NMDA receptor blocker, reduces major depression, is
in agreement with earlier findings of other glutamate antagonists (Hurley 2002; Kugaya and
Sanacora 2005; McElroy et al. 2004; Zarate et al. 2004; Zarate et al. 2006a). However, few
studies have addressed the effects of memantine on depression, and no previous studies
have examined its efficacy on alcohol dependence related depression. A study by Zarate et
al (Zarate et al. 2006b) on patients suffering severe depression did not find positive
effects with memantine at a mean dosage 19.4 mg/day compared to placebo. The difference in
the efficacy of memantine could be due to the different patient selection criteria which
included therapy-resistant depressive patients and substance abuse as an exclusion
criterion, while in this study all patients suffered from major depression comorbid with
alcohol dependence.
6.4.2 Cognition
The CERAD cognitive test battery was within normal ranges at baseline and there were no
significant differences in the follow-up in either of the treatment groups. The good
cognitive performance among these depressive alcoholics was surprising. One reason for
this is probably that these patients were still a selected population of people seeking
help and already within the social care system. Their basic needs for nutrition and
medical care was met. Although depression in itself can cause memory problems
(Paelecke-Habermann et al. 2005), it seems that CERAD is not sensitive to this impairment
(Collie et al. 1999).Thus it was not surprising that the performance in CERAD did not
change during this trial. The cognitive impairment among alcoholics needs further
investigation with a more sensitive test. It is important to determine, whether the
impairment is due to alcohol or its metabolites, or it is caused by increased accidents
and violence.
6.4.3 Quality of life
Quality of life improved in both groups significantly. The results are quite analogous to
depression scale results as noticed recently (Saarni et al. 2007) and are otherwise
difficult to explain. Quality of life scales reduced in both groups, with no difference
between groups.
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6.4.4 Alcohol consumption and craving
Both escitalopram and memantine groups had highly significant decreases from baseline in
craving for alcohol as measured with the OCDS test, on both OCDS subscales, and on AUDIT
and the AUDIT measures of alcohol consumption and of heavy drinking days. When comparing
these two compounds, memantine was at least as effective as escitalopram for reducing
alcohol craving, obsessive thoughts of drinking, compulsive drinking, alcohol consumption
and maintaining abstinence. There was a general trend for memantine to produce better
results than escitalopram, particularly in the latter half of the 26-week study period.
The trend only occasionally reached significance and never for the entire treatment
period. The efficacy for memantine is consistent with that usually found for acamprosate,
another glutaminergic compound (Croissant et al. 2006; Kiefer et al. 2005; Krystal et al.
2003; Nagy 2004). The patient compliance was good. This study corroborates a recent study
by Krupitsky et al. (Krupitsky et al. 2007), who reported that memantine reduced alcohol
cue-induced craving in recovering alcoholics. Evans et al. (Evans et al. 2007) found no
effect of memantine in patients who were actively drinking at the beginning of treatment.
This is analogous with our findings that such patients have a higher drop out rate than
those who were abstinent at the start of the treatment. This may be due to the severity of
alcohol problems but, in addition, it also could reflect the characteristics of the
possible anti-craving property of memantine (Holter et al. 1996). However, one wish for
this study was to find out a new treatment alternative for those alcoholics who cannot
stop drinking, and here it failed.
6.4.5 Comparison of decrease in depression and alcohol use
The association between decreases in depression and alcohol use has been debated for
years. The clinicians working primarily in psychiatric settings tended to see depression
as an independent entity or even as the causal factor driving the addiction. according to
that opinion, the treatment should be focused on depression. The clinicians working in the
treatment of alcohol problems, on the contrary, tended to view depression as a symptom of
addiction, which would resolve if the addiction were properly treated (Nunes and Levin
2006). The research in the field of the treatment of this comorbidity has been meagre, and
the treatment studies with SSRI still rare. Comparing to the earlier finding that the
change in drinking does not correlate significantly with the change in depression
(Cornelius et al. 1997), in this study, there was some correlation in a group of patients
in the escitalopram group.
6.4.6 Predictors in treatment of major depression comorbid with alcohol
dependency
The finding that escitalopram, in reducing depression in patients with depression comorbid
with alcohol dependence increased greatly with the age of onset of depression, is a novel
one. It is consistent, however, with a previous finding that adolescent patients with
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major depression and alcohol dependence did not show up a favorable clinical course
regarding depression when treated with another SSRI, fluoxetine (Cornelius et al. 2005).
In our study, favorable escitalopram response was also predicted by low psychic anxiety
and low pessimism, and good memantine response by lack of family history of alcoholism and
depression at the baseline.
The research findings on the relationship between age of onset and antidepressant efficacy
has been inconsistent. It is supposed that later onset of depression is a predictor of a
positive response to antidepressant treatment (Bagby et al. 2002) and has been connected
to a less malignant course of depression (Klein et al. 1999; O’Leary et al. 2000). In a
European multicenter study, the early age at onset of MDD was associated with
treatment-resistant depression (Souery et al. 2007). Such connection was not found in the
recent STAR*D study with the response to citalopram (Zisook et al. 2007). In contrast to
the situation in the STAR*D study, where the patients came from primary care or
psychiatric care practices, our patients were treatment seeking for their alcohol
dependence. In the STAR*D study, 24% of patients had dual diagnoses, but separate analysis
of those patients was not performed.
In our study the relationship between age of onset and efficacy is completely different
for the two medicines. Both reduced depression equally well, but only the efficacy with
escitalopram was related to age of onset. There was a highly significant interaction
between the two medicines with respect to the relationship to onset.
The reason why the patients with early onset of MDD had an inferior treatment response in
the escitalopram group is unclear. One explanation could be the manifestation of bipolar
depression. In a study of prevalence, correlates, disability and comorbidity of DSM-IV
Alcohol Abuse and Dependence in the United States, the association between bipolar I and
II disorders and alcohol dependence were almost twice as prevalent as comorbidity with
major depressive disorder and alcohol dependence (Hasin et al. 2007). In addition, adults
with early onset MDD are suggested to be at high risk of progression to bipolar disorder
(Smith et al. 2005). According to that finding, it should be expected that more patients
would have suffered from bipolar disorder. Although the patients in this study did not
fulfill the criteria of bipolar I and II disorders using SCID-interview, the possibility
that cannot be excluded that in this study, the bipolar diagnosis was missed because the
possible manic or hypomanic episodes were masked by periods of alcohol intoxication.
Perhaps some bipolar II or bipolar NOS diagnoses were missed. Therefore, it is possible
that the association of the early onset of the first depressive episode with the
unfavorable treatment response with escitalopram is related to depression in the bipolar
spectrum (Angst et al. 2006; Benazzi and Akiskal 2007). Another explanation could be the
impact of early childhood traumas resulting in increased vulnerability to depression,
instead of slowly acting serotonin transporter (Caspi et al. 2003) where the serotonin
reuptake inhibitor does not help. In addition, the depression in immature brains can
induce such dysfunction, e.g. in HPA-axel, that increases the vulnerability to
therapy-resistant depression (Rao 2006). The negative and hostile self-concept during a
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major depressive episode in childhood or adolescence may as well produce depression
comorbid with personality disorders, that weakens the influence of SSRIs (Bagby et al.
2002).
Although pessimism may predict suicidality in depressed patients (Oquendo et al. 2004)
very little is known whether pessimism could indicate poor treatment prognosis as well.
This study’s finding that escitalopram-treated non-responders showed more pronounced
pessimism at the baseline is in line with a recent study that showed that hopelessness is
associated with poorer response of treatment with fluoxetine in MDD (Papakostas et al.
2007),
6.4.7 Predictors in treatment of alcohol dependence comorbid with major
depression
Few possible specific predictive elements for the treatment of alcohol dependence comorbid
with major depressive disorder with either escitalopram or memantine were observed. One
predictor observed was the early age at onset of intoxicative alcohol consumption, which
leads to poor treatment outcome with escitalopram but not with memantine. The poor outcome
with escitalopram in alcohol abuse is in agreement with a previous finding that early
onset of alcohol use is a predictor for poor treatment outcome with SSRI fluvoxamine
(Chick et al. 2004). This study’s finding may suggest that memantine could be useful
treatment for type 2 alcoholics (early onset) comorbid with depression.
6.4.8 Comparison of predictors in depression and alcohol use
The finding that the early onset of the first depressive episode is a negative predictor
for escitalopram treatment in alcohol dependence confirms this study’s previous finding on
treatment of this comorbidity regarding major depressive disorder in patients with this
dual diagnoses (Muhonen et al. 2008c).
6.4.9 Serotonin transporter gene as a predictor
Serotonin transporter gene (5-hydroxy tryptamine linked polymorphic region, 5-HTTLPR) is
one of the most important genes related to major depression. Serotonergic
neurotransmission is connected to both major depression and alcohol dependence (Kranzler
and Anton 1994). Serotonin neurotransmission is regulated by 5-HTT gene and the gene
expression is regulated by 5-HTTLPR polymorphism. The research on association of
5-HTTLPR gene polymorphism and treatment response with SSRIs has been inconsistent
(Kraft et al. 2007; Serretti et al. 2007). In both those studies, the patient selection
consists of primary depressive patients. There seems to be no former studies of treatment
response to SSRI with (5-HTTLPR) variations in a group of alcohol dependent patients
comorbid with major depressive disorder. The treatment response was studied of escitalopram
comparing with the 5-HTTLPR polymorphism versus those of memantine, a glutamate NMDA
receptor modulator, which is not associated with serotonergic pathways. In this study,
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the L-allele correlates with the positive treatment response measured with MADRS in
escitalopram group, but not in memantine group. The finding is presumably connected to
the limited patient selection in comorbidity with alcohol dependence. This study limits
in depressive patients comorbid with alcohol dependence; the patients are collected
from alcohol treatment units and may thus represent a genetical subgroup of MDD.
This finding may give some hope, that more detailed diagnostical patient selections and
gene tests could give better treatment options to different patient groups, who suffer
from depressive disorders.
However, decrease in alcohol use, measured with AUDIT, was not connected to L-allele in
either treatment group.
6.5 Limitations
One limitation of the study includes the fact that there was no placebo group (Koponen and
Lepola 2005). In prior studies the placebo-effect is considered to be remarkable in this
population (Nunes and Levin 2004). It is possible that a part of the improvement of
depression was due to the placebo-effect or the natural episodic course of depression.
Nevertheless, the mean prior duration of depression in this study’s sample was 35 months,
and most of the patients suffered mainly from chronic major depression.
The drinking results were limited by the lack of baseline data before treatment for
alcohol consumption, abstinent days and heavy drinking days. Even when the AUDIT and
OCDS scores decreased throughout the treatment period, whether the relative high
number of abstinence days throughout the treatment period is actually different from
those before treatment, remains unproved. In addition, one limitation is that neither
of these medicines were accepted for treatment of alcoholism. So the results according
to alcohol treatments are preliminary and need further investigation.
Another limitation is that the total number of patients may have been too low to detect a
significant difference between two active treatments. In addition, the late gathering of
blood samples for 5-HTTLPR polymorphism posed a reduction of DNA-samples of patients, and
the significance of results. Also in addition, the patients were gathered from municipal
A-clinics, and represent group of treatment-seeking patients, who are aware of their
problems, and the results are not to be generalized to the total group of alcohol
dependent patients comorbid with major depression.
One possible limitation is that all study patients were Caucasians and do not represent a
multicultural and multiracial groups of patients comorbid with major depressive disorder
comorbid with alcohol dependence.
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7   CONCLUSIONS AND FUTURE IMPLICATIONS
The glutamate NMDA receptor modulator memantine and a SSRI escitalopram seem to be
potentially effective and safe for the treatment of major depression comorbid with alcohol
dependence.
Among this group of patients, the abstinence should be required before medication with
antidepressant drugs to avoid the early termination of the medical treatment.
According to this study, the diagnosis of comorbid Alcohol Dependence with Major
Depression, consists of different etiology, both genetically and environmentally,
subgroups. This comorbidity seems to consist of heterogenic diagnostical subgroups of
patients, and their treatment requires good diagnostical and clinical professional skills.
It is not impending that there could be one treatment option for all patients with
comorbid alcohol dependence and major depressive disorder, but different treatment
alternatives for different subgroups should be investigated to detect an individual
treatment for each patient. New treatment studies should be based on careful patient
selection inside of this comorbidity. Genetic research would be of greatest importance to
diagnostical accuracy and to understand the response to different medicines in groups of
alcohol dependent patients suffering from major depressive disorder.
The finding of the age at the first depressive episode as a predictor for escitalopram
treatment emphasizes the importance of a clinician to make a good anamnestic and clinical
exploration of the patient before beginning the treatment.
The treatment of children with depressive features should be devised to recognize those
who are at an increased risk of developing addictive disorders.
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